



Aeras' TB Vaccine Candidate Pipeline

AERAS-422 (rBCG)

Aeras (Phase I)

Recombinant BCG which over-expresses antigens 85A, 85B, 10.4, Rv3407 and 40DosR proteins and performs pro-apoptotic endosome escape

AERAS-402/Crucell Ad35

Aeras, Crucell (Phase II/IIb)

Recombinant adenovirus 35 with antigens 85A, 85B and 10.4 to boost BCG or rBCG

MVA85A/AERAS-485

Oxford Emergent Tuberculosis Consortium and Aeras (Phase IIb)

Recombinant modified vaccinia vector, expressing high levels of antigen 85A by CD4+ T cells to boost BCG or rBCG

M72

GSK, Aeras (Phase II)

Fusion molecule composed of a protein from the PPE family (Rv1196), combined with an inactive serine protease (Rv0125) to boost BCG or rBCG

SSI HyVac 4

(AERAS-404)

Sanofi Pasteur/SSI/

Intercell, Aeras (Phase I)

Recombinant M.tb antigens 85B and 10.4 combined with adjuvant IC31 to boost BCG or rBCG

Leading the Global Effort for New TB Vaccines

- **Tuberculosis knows no borders, and current tools are not enough to control a pandemic** that is becoming increasingly severe and complex due to drug resistant forms of TB and the deadly relationship between TB and HIV. TB is the leading cause of death among people also infected with HIV in Africa.
- **A modern, safe and effective vaccine is urgently needed** to prevent all forms of tuberculosis, in all age groups, including in people living with HIV.
- **The Aeras Global TB Vaccine Foundation (www.aeras.org) is a global non-profit research organization** working as a Product Development Partnership (PDP) with scientists, academic institutions, industry, foundations and governments throughout the world to ensure the rapid development and ample distribution of vaccines to eliminate TB.
- **Since its founding in 2003, Aeras has established itself as a global leader in TB vaccine research** with expertise in vaccine discovery, immunology, manufacturing and clinical testing. With its manufacturing facility and partnerships, Aeras can reduce the cost and time to manufacture TB vaccines and produce enough vaccine to meet the worldwide need.
- **Aeras' goal is to develop, test, characterize, license, manufacture and distribute** a new TB vaccine regimen following a "prime-boost" vaccine strategy that is highly promising for prevention of the disease, and to ensure the regimen's availability to all who need it.
- **Aeras has assembled the broadest TB vaccine product pipeline in the world.** With its partners in Africa, Asia, Europe and North America, Aeras has invented or supported the development of six TB vaccine candidates. Five TB vaccine candidates are in Phase I/Phase II/IIb human trials.
- **Aeras is collaborating with local research partners in Africa and Asia to prepare for and conduct TB vaccine clinical trials,** supporting the infrastructure and capacity of researchers and institutions in endemic countries.
- **Aeras uses cutting-edge science,** drawing on 20 years of basic research in antigen identification and testing, as well as the mapping of the human genome and modern biotechnologies. Aeras and its partners around the world work synergistically on vigorous, cutting-edge science, and are pursuing new and innovative approaches to TB vaccine development and delivery, including an improved recombinant BCG and aerosol vaccine delivery.
- **Aeras operates on an industrial model that involves making tough decisions** while weighing risks, resources and time – valuable time while millions are suffering and dying.
- **TB vaccine development is a scientifically complex and expensive process.** We believe that with sufficient resources and positive results from the current clinical trials, we anticipate a new TB vaccine could be available by the end of the decade.

The Aeras Global TB Vaccine Foundation is grateful for the support of the Bill & Melinda Gates Foundation, the US Food and Drug Administration, the National Institute of Allergy and Infectious Diseases, the Netherlands Ministry of Foreign Affairs, the UK Department for International Development, and the Research Council of Norway.